Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Shares Outstanding for 16 consecutive years, with $90.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 5.97% to $90.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $90.9 million, a 5.97% increase, with the full-year FY2024 number at $86.3 million, up 12.68% from a year prior.
  • Shares Outstanding was $90.9 million for Q3 2025 at Gyre Therapeutics, roughly flat from $90.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $90.9 million in Q3 2025 to a low of $12340.0 in Q3 2023.
  • A 5-year average of $58.2 million and a median of $63.6 million in 2021 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: tumbled 99.96% in 2023, then soared 694952.88% in 2024.
  • Gyre Therapeutics' Shares Outstanding stood at $63.6 million in 2021, then changed by 0.0% to $63.6 million in 2022, then grew by 20.46% to $76.6 million in 2023, then rose by 12.68% to $86.3 million in 2024, then grew by 5.31% to $90.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Shares Outstanding are $90.9 million (Q3 2025), $90.8 million (Q2 2025), and $87.6 million (Q1 2025).